Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15 year follow up of a phase II study from MD Anderson Cancer Center

BACKGROUND: Mantle cell lymphoma remains an aggressive and incurable malignancy. Intensive chemotherapy regimens containing cytarabine have substantially improved remission durability and overall survival, particularly in younger adults. However, there have been no long-term follow-up results for pa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Haematol
Hlavní autoři: Chihara, Dai, Cheah, Chan Yoon, Westin, Jason R., Fayad, Luis E., Rodriguez, Maria Alma, Hagemeister, Fredrick B., Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Cabanillas, Fernando, Kantarjian, Hagop, Kwak, Larry W., Wang, Michael L., Romaguera, Jorge E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5471614/
https://ncbi.nlm.nih.gov/pubmed/26648336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13796
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky